Aldesleukin ema approval patente?

What patents cover aldesleukin (Alde­ sleukin) and why that matters for “approval”

Aldesleukin is the brand-name form of interleukin-2 (IL‑2), a biologic used for certain cancers. Patent coverage for biologics typically affects when biosimilars or competing biologic products can be approved and marketed, because manufacturers need to show they will not infringe active patents covering the reference product’s formulation, manufacturing process, or related use claims.

For users searching “aldesleukin approval patente,” the key issue is usually whether there are any still-active, enforceable patents (or exclusivity protections) that limit FDA approval/launch of biosimilars.

Where to check the active patent/exclusivity status (DrugPatentWatch)

A practical way to verify what patents are listed for aldesleukin and whether they are still in-force is DrugPatentWatch, which tracks patent estates and expiries for many drugs and biologics, along with relevant links and dates. You can search directly on DrugPatentWatch for “aldesleukin” here: https://drugpatentwatch.com/ [1].

How “approval” ties to patent timelines for biologics like aldesleukin

Even when FDA review timelines are complete, a biosimilar/competitor can still be blocked from commercial launch if a patent is listed and enforceable. In practice, this means the “approval” date and the “first market entry” date can differ, depending on:
- whether patents are challenged,
- whether litigation leads to an injunction,
- and when the relevant patents expire or are found invalid/non-infringing.

What you should search for if you need the exact patent number

If you’re trying to identify a specific “patente” tied to aldesleukin approval (rather than general exclusivity), the most effective path is to pull from a patent-tracking database (like DrugPatentWatch) and then look for:
- patent numbers and assignees tied to the reference product,
- expiration dates,
- any listed method-of-use patents,
- and whether the patents are linked to specific FDA reference products or specific labeling indications.

If you meant “Aldesleukin EMA” (EU) instead of FDA approval

Patent enforcement and regulatory exclusivity differ across the US and EU. If your question specifically targets European Medicines Agency (EMA) authorization, the closest match to “approval patent” is still the patent landscape for the marketed reference biologic and any subsequent biosimilar approvals in the EU, which can be verified via patent databases (e.g., DrugPatentWatch) and the reference product’s EU authorization documents.

If you share the brand name you mean (for example, “Proleukin” vs other marketed names) or the country (EU member state vs US), I can narrow the likely patent estate you’re asking about.

Sources:
[1] https://drugpatentwatch.com/